Evaluation of fibrin sealing for cardiovascular surgery.
Hemorrhage remains a problem in patients undergoing cardiovascular surgery. To evaluate fibrin sealant, a completely biodegradable hemostatic agent, three series of experiments were performed in mongrel dogs. In series I, 18 dogs had a 7 cm interposition of knitted Dacron (water porosity 1500 ml/min/cm2) in the descending aorta. In group A, all prostheses were treated with fibrin sealant and in group B by blood preclotting. Measurements of blood loss demonstrated 1.29 +/- 0.26 ml/min in group A as compared with 30.16 +/- 2.85 ml/min in group B (p less than .001). In series II, six dogs of each group were compared for thrombogenicity and platelet survival by using indium-111-labeled autologous platelets. According to Goldman et al., the thrombogenicity index was calculated. The mean thrombogenicity index for group A was 0.23 +/- 0.02 in contrast to 0.33 +/- 0.05 for group B (p greater than .05). Mean platelet survival was 5.59 +/- 0.23 days in group A in contrast to 5.34 +/- 0.05 days in group B (p greater than .05). In series III, the gluing potential was investigated by creating four types of injuries: four dogs had an aortic stab wound 3 to 5 mm, six dogs received a 10 to 15 mm stab wound to the left ventricle, seven dogs had a 3 cm laceration of the left atrial appendage, and four dogs had bilateral division of their carotid arteries. Wounds of the aorta and left atrial appendage were treated by partial clamping and the sole use of fibrin sealant, the carotid arteries were repaired by four simple sutures and fibrin sealant, and the left ventricular stab wounds were treated by the combined use of heterologous collagen and fibrin sealant without suture.(ABSTRACT TRUNCATED AT 250 WORDS)
D000818:Animals; D001021:Aortic Valve; D001792:Blood Platelets / Q000187:drug effects; D013504:Cardiovascular Surgical Procedures; D002470:Cell Survival / Q000187:drug effects; D004285:Dogs; D004338:Drug Combinations / Q000009:adverse effects / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D005176:Factor XIII / Q000009:adverse effects / Q000627:therapeutic use*; D005337:Fibrin / Q000009:adverse effects / Q000627:therapeutic use*; D015718:Fibrin Tissue Adhesive; D005340:Fibrinogen / Q000009:adverse effects / Q000627:therapeutic use*; D005353:Fibronectins / Q000009:adverse effects / Q000627:therapeutic use*; D006350:Heart Valve Prosthesis; D006490:Hemostatics / Q000009:adverse effects / Q000627:therapeutic use; D013917:Thrombin / Q000009:adverse effects / Q000627:therapeutic use*; D013927:Thrombosis / Q000139:chemically induced; D013997:Time Factors; D014014:Tissue Adhesives / Q000009:adverse effects / Q000627:therapeutic use*
D004338:Drug Combinations; D015718:Fibrin Tissue Adhesive; D005353:Fibronectins; D006490:Hemostatics; D014014:Tissue Adhesives; D005337:Fibrin; D005340:Fibrinogen; D005176:Factor XIII; D013917:Thrombin